NASDAQ:MBX
MBX Biosciences, Inc.
MBX Biosciences, Inc. reported net income of −$87.0M in fiscal 2025. Free cash flow was −$81.9M, and the diluted share count rose 243.0%.Summary generated from MBX Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−27.8%
Debt / equityn/a
Free cash flow−$81.9M
FCF marginn/a
Share count change+243.0%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −35 | −68 | −98 |
| Net income | −33 | −62 | −87 |
| Free cash flow | −32 | −56 | −82 |
Recent filings
- 8-KRegulation FD disclosure
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Aug 5, 2026 - 4Insider transaction report
Aug 4, 2026 - 8-KDirector or officer change
Jul 13, 2026 - 8-KRegulation FD disclosure
Jun 12, 2026 - 8-KDirector or officer change
Jun 5, 2026